CSL - Science Center Research Acceleration Initiative

Working together to identify and commercialize promising new technologies at research and academic institutions across the region

CSL – Sc RAI is now closed for applications.  THANK YOU to all the researchers who submitted pre-proposal applications to our 2020 round.


March 2                      Opening day for pre-proposal submissions

April 27                       Deadline for receipt of pre-proposal submissions

June 5                          Finalist selected, invited to present virtually to CSL the week of July 13

July 27, 2020             RAI Awardees selected for funding (up to 3 proposals @ up to $200K/year for 2 years)


For questions regarding the Initiative and details of partnering with CSL, email: RAI.US@cslbehring,com or contact



CSL Behring is a leading global biotechnology company that develops and delivers innovative biotherapies to help people living with life threatening medical conditions live full lives. CSL has partnered with the Science Center, a nonprofit institution that is dedicated to identifying and nurturing promising technology for over half a century, to build the CSL-Science Center Research Acceleration Initiative (CSL-Sc RAI). The initiative is designed to source research and fast-track discovery through partnerships between CSL and leading life sciences research institutions. Selected projects receive funding and access to industry resources for scientists working on novel technologies in CSL’s therapeutic areas.


funding mechanism


The Research Acceleration Initiative is a partnership, with university investigators, intended to further develop promising new technologies.  The process begins with the submission of a preproposal by interested investigators.  These applications should include a non-confidential description of the technology, the proposed market and a general research plan to increase the idea’s commercial readiness.


Preproposals will be reviewed within CSL, and a number of finalists will receive invitations to present in person a more detailed description of the opportunity.


Selected awardees will then be engaged by CSL with two aims.  The first will be to establish a final research plan in conjunction with CSL scientists and bringing to bear CSL resources that might not be independently available to the research team.  The second will be to begin negotiations with the hosting technology transfer office to formalize the relationship via a research and option agreement.


Once the research and option agreement has been executed the project will commence.


The Initiative will fund up to three proposals in 2020. Successful applicants will receive up to $200,000 per year for up to two years (maximum $400,000 funding) to accelerate translation of their research. Because the funding will be in the form of research partnerships, interested investigators must engage their  institution’s technology transfer office prior to submitting an application.


The CSL – Science Center Research Acceleration Initiative seeks innovations that address CSL Therapeutic and Focus areas, and that are amenable to or include a listed Modality below:

Therapeutic areas

(Emphasis on rare disease)

  • Immunology
  • Neurology
  • Haematology
  • Thrombosis
  • Transplant
  • Respiratory
  • Cardiovascular / Metabolic

focus areas

  • Novel drug targets
  • Novel therapeutic candidates
  • Novel strategies for treating disease



  • Antibodies
  • Protein therapeutics
  • Gene therapies
  • Cell therapies
  • Small molecules not of interest


Why collaborate with CSL? 


Global capabilities on your doorstep


Work with one of the world's leading biotech companies


Funding for successful proposals


Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise


Accelerate Translation of your research to deliver new therapies to patients


Sharon Ross

Program Manager